Literature DB >> 33675006

Mesenchymal Stem Cell-Based Therapy for Diabetes Mellitus: Enhancement Strategies and Future Perspectives.

Haisen Li1,2,3, Hao Zhu3, Ting Ge4, Zhifeng Wang5,6,7, Chao Zhang8,9.   

Abstract

Diabetes mellitus (DM), a chronic disorder of carbohydrate metabolism, is characterized by the unbridled hyperglycemia resulted from the impaired ability of the body to either produce or respond to insulin. As a cell-based regenerative therapy, mesenchymal stem cells (MSCs) hold immense potency for curing DM duo to their easy isolation, multi-differentiation potential, and immunomodulatory property. However, despite the promising efficacy in pre-clinical animal models, naive MSC administration fails to exhibit clinically satisfactory therapeutic outcomes, which varies greatly among individuals with DM. Recently, numbers of innovative strategies have been applied to improve MSC-based therapy. Preconditioning, genetic modification, combination therapy and exosome application are representative strategies to maximize the therapeutic benefits of MSCs. Therefore, in this review, we summarize recent advancements in mechanistic studies of MSCs-based treatment for DM, and mainly focus on the novel approaches aiming to improve the anti-diabetic potentials of naive MSCs. Additionally, the potential directions of MSCs-based therapy for DM are also proposed at a glance.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Combination therapy; Diabetes mellitus; Exosome; Genetic modification; Mesenchymal stem cells; Preconditioning

Mesh:

Year:  2021        PMID: 33675006     DOI: 10.1007/s12015-021-10139-5

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  128 in total

Review 1.  The bioenergetics of inflammation: insights into obesity and type 2 diabetes.

Authors:  K N Keane; E K Calton; R Carlessi; P H Hart; P Newsholme
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

Review 2.  Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Authors:  Julie B Sneddon; Qizhi Tang; Peter Stock; Jeffrey A Bluestone; Shuvo Roy; Tejal Desai; Matthias Hebrok
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

3.  Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind.

Authors:  Judith E Fradkin; Griffin P Rodgers
Journal:  Ann Intern Med       Date:  2017-01-03       Impact factor: 25.391

Review 4.  Mechanisms of diabetic complications.

Authors:  Josephine M Forbes; Mark E Cooper
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

Review 5.  Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management.

Authors:  Arun Chaudhury; Chitharanjan Duvoor; Vijaya Sena Reddy Dendi; Shashank Kraleti; Aditya Chada; Rahul Ravilla; Asween Marco; Nawal Singh Shekhawat; Maria Theresa Montales; Kevin Kuriakose; Appalanaidu Sasapu; Alexandria Beebe; Naveen Patil; Chaitanya K Musham; Govinda Prasad Lohani; Wasique Mirza
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-24       Impact factor: 5.555

6.  TRB3 mediates advanced glycation end product-induced apoptosis of pancreatic β-cells through the protein kinase C β pathway.

Authors:  Meng Wang; Wenjian Zhang; Shiqing Xu; Liang Peng; Zai Wang; Honglin Liu; Qing Fang; Tingting Deng; Xiuli Men; Jinning Lou
Journal:  Int J Mol Med       Date:  2017-05-16       Impact factor: 4.101

7.  Protein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts.

Authors:  Christoph Nowak; Johan Sundström; Stefan Gustafsson; Vilmantas Giedraitis; Lars Lind; Erik Ingelsson; Tove Fall
Journal:  Diabetes       Date:  2015-09-29       Impact factor: 9.461

Review 8.  Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?

Authors:  Anna Grohová; Klára Dáňová; Radek Špíšek; Lenka Palová-Jelínková
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

Review 9.  Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives.

Authors:  Varun Pathak; Nupur Madhur Pathak; Christina L O'Neill; Jasenka Guduric-Fuchs; Reinhold J Medina
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-05-03

Review 10.  Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.

Authors:  Mohamed M Kamal; Dina H Kassem
Journal:  Front Cell Dev Biol       Date:  2020-01-29
View more
  4 in total

1.  Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling.

Authors:  Yi Liu; Jingan Chen; Haowei Liang; Yueqin Cai; Xinyue Li; Li Yan; Li Zhou; Letian Shan; Hui Wang
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

2.  Comparative Analysis of the Therapeutic Effects of Amniotic Membrane and Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes.

Authors:  Zhifeng Wang; Haisen Li; Jingmeng Fang; Xiaoyu Wang; Shuhang Dai; Wei Cao; Yinhong Guo; Zhe Li; Hao Zhu
Journal:  Stem Cell Rev Rep       Date:  2022-01-11       Impact factor: 6.692

Review 3.  Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects.

Authors:  Meirong Li; Yufeng Jiang; Qian Hou; Yali Zhao; Lingzhi Zhong; Xiaobing Fu
Journal:  Stem Cell Res Ther       Date:  2022-04-04       Impact factor: 6.832

Review 4.  From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.

Authors:  Ayman F Refaie; Batoul L Elbassiouny; Malgorzata Kloc; Omaima M Sabek; Sherry M Khater; Amani M Ismail; Rania H Mohamed; Mohamed A Ghoneim
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.